Tourmaline Bio stock hits 52-week high at 47.69 USD

Tourmaline Bio (TRML) has agreed to be acquired by Novartis for $1.4 billion, or $48 per share, driven by Novartis's interest in its late-stage IL-6-targeting antibody for atherosclerotic cardiovascular disease. The acquisition, expected to close in Q4 2025, follows TRML's recent 52-week high of $47.69 and has led several analyst firms, including Jefferies, Guggenheim, and Wedbush, to downgrade the stock to Hold/Neutral with price targets aligned to the $48 offer, effectively capping immediate upside and reflecting the market's assessment of the deal's valuation.

Analysis

Tourmaline Bio (TRML) has entered a definitive agreement to be acquired by Novartis for $1.4 billion, translating to $48.00 per share. The acquisition is strategically driven by Novartis's interest in Tourmaline's late-stage IL-6-targeting antibody, pacibekitug, for cardiovascular disease, with an expected closing in Q4 2025. This announcement follows a period of significant appreciation for TRML, which recently hit a 52-week high of $47.69, marking a 192.56% gain over the past six months. Despite the company's strong liquidity, evidenced by a current ratio of 24.68, market indicators suggest the stock is in overbought territory. In response to the acquisition, which is seen as fairly valued, analyst firms including Jefferies, Guggenheim, and Wedbush have downgraded TRML to Hold or Neutral, adjusting their price targets to align with the $48 offer. This consensus indicates that the market views the stock as fully priced, with its value now anchored to the transaction price, effectively capping further upside potential pending deal completion.

Key Decisions for Investors

• For existing Tourmaline Bio shareholders, the acquisition by Novartis at $48 per share effectively caps the stock's upside, making it prudent to consider liquidating positions to realize gains, as the current price near $47.69 offers minimal further appreciation.
• New investments in Tourmaline Bio are not advised, as the stock is trading at the acquisition valuation, leaving no meaningful upside for new capital while retaining downside risk should the deal fail to close.
• Investors should now view TRML primarily through a merger arbitrage lens, monitoring the spread between the market price and the $48 offer for any signs of increasing deal risk ahead of the projected Q4 2025 close date.